UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

DODD 6200.2(D)

USE OF INVESTIGATIONAL NEW DRUGS FOR FORCE HEALTH PROTECTION

inactive, Most Current
Organization: DODD
Publication Date: 1 August 2000
Status: inactive
Page Count: 13
scope:

This Directive:

Applies to the Office of the Secretary of Defense, the Military Departments, the Chairman of the Joint Chiefs of Staff, the Combatant Commands, the Office of the Inspector General of the Department of Defense, the Defense Agencies, the DoD Field Activities and all other organizational entities within the Department of Defense (hereafter referred to collectively as "the DoD Components").

Applies to all uses of investigational new drugs by the Department of Defense for force health protection.

Does not apply to actions by DoD healthcare providers that are within standard medical practice in the United States and are not subject to FDA regulations at reference (c).

(e) DoD Directive 1404.10, "Emergency-Essential (E-E) DoD U.S. Citizen Civilian Employees," April 10, 1992

(f) DoD Instruction 3020.37, "Continuation of Essential DoD Contractor Services During Crises," November 6, 1990

Document History

DODD 6200.2(D)
August 1, 2000
USE OF INVESTIGATIONAL NEW DRUGS FOR FORCE HEALTH PROTECTION
This Directive: Applies to the Office of the Secretary of Defense, the Military Departments, the Chairman of the Joint Chiefs of Staff, the Combatant Commands, the Office of the Inspector General of...

References

Advertisement